Longeveron Inc.
- LGVN
- NASDAQ
- Biotechnology
- Cell-based Therapies
- Age-related Disease Treatments
$1.39
Today −0.36%Quote Oct 19, 2026, 08:00 PM UTC
−44.18%over the last month
Max drawdown −52.2%From 1-month high −52.2%3 months −77.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Longeveron
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses.
Where the money comes from
Q1 2021 revenue $376,000
- AlzheimersAssociationGrantMember$170,00045.2%
- ClinicalTrialRevenueMember$165,00043.9%
- MarylandTEDCOGrantMember$41,00010.9%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
38
Market value
$4.2M
Quote Oct 19
Analyst target
$10.00
+619.4% from here
Floor
$0.98
29.3% below price
Resistance
$1.77
27.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LGVNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free